Zhengfang Yi
Overview
Explore the profile of Zhengfang Yi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
2559
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang J, Zhang L, Ding X, Wu M, Zhang D, Wu Y, et al.
Eur J Med Chem
. 2025 Jan;
285:117240.
PMID: 39788064
Interferon regulatory factor 4 (IRF4) is specifically overexpressed in multiple myeloma (MM) and mediates MM progression and survival, making it an emerging target for MM treatment. However, no chemical entity...
2.
Lv S, Zhang L, Wu M, Zhu S, Wang Y, Liu L, et al.
Cell Oncol (Dordr)
. 2024 Nov;
47(6):2233-2246.
PMID: 39565508
Ovarian cancer, a leading cause of gynecological cancer deaths globally, poses significant treatment challenges. Cisplatin (CDDP) is the first treatment choice for ovarian cancer and it is initially effective. However,...
3.
Xing Y, Guo W, Wu M, Xie J, Huang D, Hu P, et al.
Mol Cancer Ther
. 2024 Oct;
24(1):81-92.
PMID: 39387112
The B-cell lymphoma 6 (BCL6) transcription factor plays a key role in the establishment of germinal center (GC) formation. Diffuse large B-cell lymphoma (DLBCL) originates from the GC reaction due...
4.
Wu M, Zhang L, Pi L, Liu L, Wang S, Wu Y, et al.
Cell Oncol (Dordr)
. 2024 Jun;
47(5):1797-1809.
PMID: 38888849
Purpose: Breast cancer is the most commonly diagnosed cancer in women, and triple-negative breast cancer (TNBC) accounts for approximately 15%-20% of all breast cancers. TNBC is highly invasive and malignant....
5.
Chen H, Bian A, Yang L, Yin X, Wang J, Ti C, et al.
Oncogene
. 2024 Jun;
43(27):2132-2134.
PMID: 38839943
No abstract available.
6.
Guo M, Hu P, Xie J, Tang K, Hu S, Sun J, et al.
Genes Dis
. 2024 Apr;
11(4):101164.
PMID: 38560505
Gastric cancer is highly prevalent among digestive tract tumors. Due to the intricate nature of the gastric cancer immune microenvironment, there is currently no effective treatment available for advanced gastric...
7.
Chen H, Bian A, Zhou W, Miao Y, Ye J, Li J, et al.
ACS Cent Sci
. 2024 Apr;
10(3):579-594.
PMID: 38559310
Signal transducer and activator of transcription 3 (STAT3) is an attractive cancer therapeutic target. Unfortunately, targeting STAT3 with small molecules has proven to be very challenging, and for full activation...
8.
Wu M, Xie J, Xing Y, Zhang L, Chen H, Tang B, et al.
Int J Biol Sci
. 2024 Jan;
20(2):486-501.
PMID: 38169532
Ovarian cancer is one of the tumors with the highest fatality rate among gynecological tumors. The current 5-year survival rate of ovarian cancer is <35%. Therefore, more novel alternative strategies...
9.
Ti C, Chen H, Zhou W, Bian A, Hu P, Miao Y, et al.
Int Immunopharmacol
. 2023 Dec;
127:111344.
PMID: 38086269
Objectives: Psoriasis is a prevalent chronic inflammatory skin disease in humans that is characterized by frequent relapses and challenging to cure. WB518 is a novel small molecule compound with an...
10.
Gu H, Zhang T, Guan T, Wu M, Li S, Li Y, et al.
J Med Chem
. 2023 Dec;
66(24):16917-16938.
PMID: 38054798
Myoferlin (MYOF) mediates the growth and metastasis of various cancers as an emerging therapeutic target by regulating exocytosis and endocytosis. However, the previously reported MYOF inhibitor, , failed to be...